Home
|
Learning Center
|
中文版
Publications
站内成果搜索:
搜索
Sorafenib in the treatment of thyroid cancer
Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma
Sorafenib for Hepatocellular Carcinoma: From Randomized Controlled Trials to Clinical Practice
Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulatory proteins
Sorafenib With and Without Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma With Main Portal Vein Tumor Thrombosis: A Retrospective Analysis
Sorafenib continuation or discontinuation in patients with unresectable hepatocellular carcinoma after a complete response
Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma
Sorafenib combined with radiofrequency ablation in the treatment of a patient with renal cell carcinoma plus primary hepatocellular carcinoma
Sorafenib for patients with differentiated thyroid cancer Reply
Sorafenib in Hepatitis C Virus-Negative Patients With Hepatocellular Carcinoma: Don't Throw the Baby Out With the Bathwater! Reply
Sorafenib induces variations of the DNA methylome in HA22T/VGH human hepatocellular carcinoma-derived cells
Sorafenib delivery nanoplatform based on superparamagnetic iron oxide nanoparticles magnetically targets hepatocellular carcinoma
Sorafenib tosylate inhibits directly necrosome complex formation and protects in mouse models of inflammation and tissue injury
Sorafenib controls the epithelial-mesenchymal transition of ovarian cancer cells via EGF and the CD44-HA signaling pathway in a cell type-dependent manner
Sorafenib use for recurrent hepatocellular cancer after resection or transplantation: Observations from a US regional analysis of the GIDEON registry
Sorafenib and Regorafenib in HBV- or HCV-positive hepatocellular carcinoma patients: Analysis of RESORCE and SHARP trials
Sorafenib as a potential strategy for refractory pulmonary arterial hypertension
Sorafenib induced alteration of protein glycosylation in hepatocellular carcinoma cells
Sorafenib suppresses extrahepatic metastasis de novo in hepatocellular carcinoma through inhibition of mesenchymal cancer stem cells characterized by the expression of CD90
Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma
Sorafenib Impedes Rift Valley Fever Virus Egress by Inhibiting Valosin-Containing Protein Function in the Cellular Secretory Pathway
Sorafenib in Patients with Hepatocellular Carcinoma-Results of the Observational INSIGHT Study
Sorafenib inhibits therapeutic induction of necroptosis in acute leukemia cells
Sorafenib targets the mitochondrial electron transport chain complexes and ATP synthase to activate the PINK1-Parkin pathway and modulate cellular drug response
Sorafenib-Induced Changes in Thyroid Hormone Levels in Patients Treated for Hepatocellular Carcinoma
Sorafenib inhibits growth of hepatoma with hypoxia and hypoxia-driven angiogenesis in nude mice
Sorafenib combined with hepatectomy in patients with intermediate-stage and advanced hepatocellular carcinoma
Sorafenib pretreatment enhances radiotherapy through targeting MEK/ERK/NF-kappa B pathway in human hepatocellular carcinoma-bearing mouse model
Sorafenib Inhibits Renal Fibrosis Induced by Unilateral Ureteral Obstruction via Inhibition of Macrophage Infiltration
Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial
Sorafenib-induced Thyroiditis in FMS-like Tyrosine Kinase 3-internal Tandem Duplication-mutated Acute Myeloid Leukemia
Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli
Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant
Sorafenib and novel multikinase inhibitors in AML
Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf
Sorafenib-Induced Apoptosis of Chronic Lymphocytic Leukemia Cells Is Associated with Downregulation of RAF and Myeloid Cell Leukemia Sequence 1 (Mcl-1)
Soral synapomorphies are significant for the systematics of the Ustilago-Sporisorium-Macalpinomyces complex (Ustilaginaceae)
Sorafenib-induced premalignant and malignant skin lesions
Sorafenib and pegylated interferon-alpha 2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial
Sorafenib-induced eruption resembling pityriasis rubra pilaris
Sora: High-Performance Software Radio Using General-Purpose Multi-Core Processors
Sorafenib induces partial response in metastatic medullary thyroid carcinoma
Sorafenib Therapy for Metastatic Renal Carcinoma in Patients with Low Cardiac Ejection Fraction: Report of Two Cases and Literature Review
Sorafenib Use in Hepatocellular Carcinoma in Japan: Early Experience and Impact on Clinical Practice
Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC)
Sorafenib-Induced Psoriasiform Eruption in a Patient With Metastatic Thyroid Carcinoma
Sorafenib downregulates ERK/Akt and STAT3 survival pathways and induces apoptosis in a human neuroblastoma cell line
Sorafenib as an adjuvant therapy for resectable hepatocellular carcinoma: A single center experience
Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivo
Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation
Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study
Sorafenib-induced erythema multiforme: three cases
Sorafenib before liver transplantation for hepatocellular carcinoma: risk or give up
Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells
Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer
Sorafenib in relapsed and refractory FLT3-ITD positive acute myeloid leukemia: a novel treatment option
Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: A case report
Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients
Sorafenib in clinical practice: Evidence-based use or abuse? Reply
Sorafenib in Clinical Practice: Evidence-Based Use or Abuse?
Sorafenib targets BCR kinases and blocks migratory and microenvironmental survival signals in CLL cells
Sorafenib: A Review in Hepatocellular Carcinoma
Sorafenib for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis: a systematic review of comparative studies
Sorafenib Decreases Tumor Exposure to an Anti-carcinoembryonic Antigen Monoclonal Antibody in a Mouse Model of Colorectal Cancer
Sorafenib-Regorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma: A Single-Institute Experience
Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT
Sorafenib and FH535 in combination act synergistically on hepatocellular carcinoma by targeting cell bioenergetics and mitochondrial function
Sorafenib inhibits cell growth but fails to enhance radio- and chemosensitivity of glioblastoma cell lines
Sorafenib for the treatment of breast cancer
Sorafenib in Combination With Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma
Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center
Sorafenib in squamous cell carcinoma of the head and neck: molecular basis and potential role
Sorafenib response in hepatocellular carcinoma: MicroRNAs as tuning forks
Sorafenib vs surgical resection for hepatocellular carcinoma with macrovascular invasion: A propensity score analysis
Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis
Sorafenib and fluvastatin synergistically alleviate hepatic fibrosis via inhibiting the TGF beta 1/Smad3 pathway
Sorafenib for Advanced Hepatocellular Carcinoma: A Real-Life Experience
Sorafenib improves alkylating therapy by blocking induced inflammation, invasion and angiogenesis in breast cancer cells
Sorafenib inhibited cell growth through the MEK/ERK signaling pathway in acute promyelocytic leukemia cells
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
Sora (Porzana carolina) autumn migration habitat use
Sorafenib induces renal cell carcinoma apoptosis via upregulating activating transcription factor 4
Sorafenib combined with radiofrequency ablation as treatment for patients with hepatocellular carcinoma: a systematic review and meta-analysis
Sorafenib improves lipiodol deposition in transarterial chemoembolization of Chinese patients with hepatocellular carcinoma: a long-term, retrospective study
Sorafenib and indocyanine green co-loaded in photothermally sensitive liposomes for diagnosis and treatment of advanced hepatocellular carcinoma
Sorafenib-Resistant Hepatocellular Carcinoma Stratified by Phosphorylated ERK Activates PD-1 Immune Checkpoint
Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial
Sorafenib as a Salvage Therapy in FLT3-ITD Negative Relapse/Refractory Acute Myeloid Leukemia
Sorafenib inhibits caspase-1 expression through suppressing TLR4/stat3/SUMO1 pathway in hepatocellular carcinoma
Sorafenib and docosahexaenoic acid act in synergy to suppress cancer cell viability: a role of heme oxygenase 1